1. >
  2. search-en

Search

Found 411 Results
Page 1 of 42

Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA


Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors   Paris (France), […]

06/30/2022




Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022


All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]

06/16/2022


Publication of the 2021 Annual Financial Report


Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

04/28/2022



Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer


Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

04/07/2022


Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million


Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

04/06/2022


Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022


AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

03/31/2022


Combined General Meeting (April 19, 2020 | 2:00 pm)


Extraordinary General Meeting (April 19, 2020 | 2:00 pm)

03/24/2022


Page 1 of 42

No more results